Related Experiment Video
Updated: Jun 4, 2026
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
Published on: May 26, 2015
Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
Arintaya Phrommintikul1, Srun Kuanprasert, Wanwarang Wongcharoen
1Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. apromint@mail.med.cmu.ac.th
Insights
Influenza vaccination significantly reduced major cardiovascular events in patients recently hospitalized for acute coronary syndrome (ACS). This suggests the influenza vaccine is a valuable secondary prevention strategy for ACS patients.
Area of Science:
- Cardiology
- Infectious Diseases
- Preventive Medicine
Background:
- Influenza infection exacerbates atherosclerosis and acute coronary syndrome (ACS).
- The role of influenza vaccination in preventing cardiovascular events post-ACS remains unclear.
Purpose of the Study:
- To evaluate the efficacy of inactivated influenza vaccine in reducing major cardiovascular events in patients with recent ACS.
Main Methods:
- Prospective randomized open-label study with blinded endpoints (PROBE).
- 439 patients admitted for ACS were randomized to receive influenza vaccine or no treatment.
- All patients received standard ACS therapy.
Main Results:
- The influenza vaccine group had fewer major cardiovascular events (9.5% vs. 19.3%, P=0.004).
- No significant difference was observed in cardiovascular death rates between groups (P=0.088).
Conclusions:
- Influenza vaccination demonstrated a protective effect against major cardiovascular events in ACS patients.
- The study recommends influenza vaccination for secondary prevention in patients with ACS.
Aims:
Influenza infection has been shown to accentuate the progression of atherosclerosis and precipitate the occurrence of acute coronary syndrome (ACS). However, the protective effects of the influenza vaccine on cardiovascular events are still inconclusive.
Methods And Results:
The study was a prospective randomized open with blinded endpoint (PROBE) study. The 439 patients who had been admitted due to ACS within 8 weeks were enrolled and randomly allocated to receive inactivated influenza vaccine in the vaccine group and no treatment in the control group. All patients were treated with the standard therapy including revascularization according to primary cardiologists. The primary endpoint, which was the combined major cardiovascular events, including death, hospitalization from ACS, hospitalization from heart failure, and hospitalization from stroke, occurred less frequently in the vaccine group than the control group [9.5 vs. 19.3%, unadjusted HR 0.70 (0.57-0.86), P = 0.004]. There was no significant difference in the incidence of cardiovascular death between the vaccine and control groups [2.3 vs. 5.5%, unadjusted HR 0.39 (0.14-1.12), P = 0.088].
Conclusion:
The influenza vaccine reduced major cardiovascular events in patients with ACS. Therefore, it should be encouraged as a secondary prevention in this group of patients.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:26Angina IV: Management
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations